What Biotech CEOs (And Their Funders) Learned From The Theranos Debacle

Published: Aug 02, 2017

The collapse of the diagnostic company Theranos shook the world of venture-funded biotechnology. Theranos was a “unicorn,” valued by its investors at $9 billion at one point. That made its founder, Elizabeth Holmes, the youngest woman billionaire in the world for inventing a technology that, she said, allowed pharmacies and doctors’ offices to do a bunch of medical diagnostic tests on a single drop of a person’s blood.

Back to news